The estimated Net Worth of John P Phd Longenecker is at least $779 Tisíc dollars as of 3 March 2022. John Longenecker owns over 7,000 units of Pacira BioSciences Inc stock worth over $335,699 and over the last 13 years he sold PCRX stock worth over $0. In addition, he makes $442,946 as Independent Director at Pacira BioSciences Inc.
John has made over 15 trades of the Pacira BioSciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of PCRX stock worth $75,670 on 3 March 2022.
The largest trade he's ever made was buying 10,000 units of Pacira BioSciences Inc stock on 10 August 2018 worth over $24,500. On average, John trades about 1,644 units every 117 days since 2011. As of 3 March 2022 he still owns at least 25,823 units of Pacira BioSciences Inc stock.
You can see the complete history of John Longenecker stock trades at the bottom of the page.
DR. John P. Longenecker Ph.D. serves as Independent Director of the Company. From October 2010 until May 2014, Dr. Longenecker served as President and Chief Executive Officer of HemaQuest Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of therapeutics for blood diseases. From December 2009 to March 2010, Dr. Longenecker served as the President and Chief Executive Officer of VitreoRetinal Technologies Inc., an ophthalmic biopharmaceutical company. From February 2002 to January 2009, Dr. Longenecker was the President and Chief Executive Officer and a member of the board of directors of Favrille, Inc. In 1992, Dr. Longenecker joined DepoTech as Senior Vice President of Research, Development and Operations and then served as President and Chief Operating Officer from February 1998 to March 1999. Following SkyePharma PLC's acquisition of DepoTech in 1999, Dr. Longenecker served as President for the U.S. operations of SkyePharma, Inc. and as a member of the executive committee for SkyePharma PLC. From 1982 to 1992, Dr. Longenecker was at Scios Inc. (Cal Bio), a biotechnology company where he served as Vice President and Director of Development. Dr. Longenecker was also a director of a number of Cal Bio subsidiaries during this period, including Meta Bio and Karo Bio. Dr. Longenecker holds a B.S. in chemistry-education from Purdue University and a Ph.D. in biochemistry from The Australian National University. He was a post-doctoral fellow at Stanford University from 1980 to 1982.
As the Independent Director of Pacira BioSciences Inc, the total compensation of John Longenecker at Pacira BioSciences Inc is $442,946. There are 15 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
John's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon a Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: